AQR Capital Management
APLS

AQR Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

AQR Capital Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.2M Sell
427,970
-1,848,717
-81% -$39.8M 0.01% 1089
2025
Q4 		$57.2M Sell
2,276,687
-2,210,667
-49% -$51.9M 0.03% 637
2025
Q3 		$102M Sell
4,487,354
-1,489,060
-25% -$34.7M 0.07% 413
2025
Q2 		$103M Buy
5,976,414
+1,898,995
+47% +$35.2M 0.09% 329
2025
Q1 		$89.2M Buy
4,077,419
+2,220,977
+120% +$61.4M 0.09% 299
2024
Q4 		$59.2M Buy
1,856,442
+1,039,182
+127% +$31.3M 0.08% 334
2024
Q3 		$23.6M Buy
817,260
+570,380
+231% +$21.1M 0.03% 597
2024
Q2 		$9.18M Buy
246,880
+190,420
+337% +$8.62M 0.01% 781
2024
Q1 		$3.26M Buy
+56,460
New +$3.6M 0.01% 1192
2023
Q3 		– Sell
-10,926
Closed -$995K – 2313
2023
Q2 		$995K Sell
10,926
-4,263
-28% -$368K ﹤0.01% 1553
2023
Q1 		$1M Sell
15,189
-2,002
-12% -$116K ﹤0.01% 1549
2022
Q4 		$889K Buy
17,191
+8,792
+105% +$466K ﹤0.01% 1605
2022
Q3 		$574K Buy
8,399
+92
+1% +$5.44K ﹤0.01% 1726
2022
Q2 		$376K Buy
+8,307
New +$379K ﹤0.01% 1779
2021
Q4 		– Sell
-40,966
Closed -$1.35M – 2196
2021
Q3 		$1.35M Buy
40,966
+36,478
+813% +$2.05M ﹤0.01% 1382
2021
Q2 		$284K Buy
+4,488
New +$232K ﹤0.01% 2057
2021
Q1 		– Sell
-3,941
Closed -$225K – 2188
2020
Q4 		$225K Sell
3,941
-11,928
-75% -$505K ﹤0.01% 2055
2020
Q3 		$479K Sell
15,869
-11,044
-41% -$330K ﹤0.01% 1749
2020
Q2 		$879K Sell
26,913
-7,298
-21% -$234K ﹤0.01% 1511
2020
Q1 		$917K Buy
34,211
+13,591
+66% +$483K ﹤0.01% 1373
2019
Q4 		$631K Buy
+20,620
New +$571K ﹤0.01% 1673

Other funds holding APLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

AQR Capital Management's APLS Position: Q1 2026 in Review

AQR Capital Management reduced its Apellis Pharmaceuticals (APLS) stake by 81% in Q1 2026, selling an estimated $39.8M and leaving 427,970 shares worth $17.2M. The position accounts for 0.01% of the portfolio, ranked #1089.

AQR Capital Management first reported a position in APLS in Q4 2019 and has held it in 21 quarters since. The position peaked at $103M in Q2 2025. 323 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • AQR Capital Management held 427,970 shares of Apellis Pharmaceuticals worth $17.2M as of Q1 2026.
  • AQR Capital Management sold 1,848,717 Apellis Pharmaceuticals shares in Q1 2026, an estimated $39.8M.
  • Apellis Pharmaceuticals made up 0.01% of AQR Capital Management's portfolio in Q1 2026, its #1089 holding.
  • AQR Capital Management first reported a position in Apellis Pharmaceuticals in Q4 2019 and has held it in 21 quarters since.
  • AQR Capital Management's Apellis Pharmaceuticals position peaked at $103M in Q2 2025.
  • 323 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.